Literature DB >> 17296847

Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entity.

George K Tofaris1, Tamas Revesz, Thomas S Jacques, Savvas Papacostas, Jeremy Chataway.   

Abstract

BACKGROUND: Neurodegeneration with brain iron accumulation is a rare neurodegenerative disorder characterized by iron deposition in the basal ganglia and neuroaxonal dystrophy. Familial cases with mutations in the pantothenate kinase gene are associated with a specific phenotype. In contrast, sporadic cases are heterogeneous in their clinical presentation.
OBJECTIVE: To describe an atypical case of sporadic late-onset neurodegeneration with brain iron accumulation. DESIGN, SETTING, AND PATIENT: Case report of a patient who presented with psychiatric features at age 22 years followed by progressive gait disturbance, extrapyramidal symptoms, epilepsy, and corticospinal tract involvement.
RESULTS: Magnetic resonance imaging showed iron deposition in the globus pallidus and substantia nigra. Cortical biopsy revealed Lewy bodies with predominant alpha-synuclein and less extensive tau-positive neurites.
CONCLUSIONS: Our findings in association with previously reported cases suggest that cortical neuritic and Lewy body pathology is a feature of atypical neurodegeneration with brain iron accumulation, clinically characterized by adult onset and psychiatric symptoms. These observations raise the possibility that these cases of atypical neurodegeneration with brain iron accumulation represent a distinct clinicopathological syndrome and suggest a molecular link between iron deposition and alpha-synuclein accumulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296847     DOI: 10.1001/archneur.64.2.280

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  8 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

Review 2.  Treating Alzheimer's disease by targeting iron.

Authors:  Sara Nikseresht; Ashley I Bush; Scott Ayton
Journal:  Br J Pharmacol       Date:  2019-02-11       Impact factor: 8.739

3.  Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells.

Authors:  Qing He; Ning Song; Huamin Xu; Rong Wang; Junxia Xie; Hong Jiang
Journal:  J Neural Transm (Vienna)       Date:  2010-08-06       Impact factor: 3.575

4.  Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations.

Authors:  Coro Paisán-Ruiz; Abi Li; Susanne A Schneider; Janice L Holton; Robert Johnson; Desmond Kidd; Jeremy Chataway; Kailash P Bhatia; Andrew J Lees; John Hardy; Tamas Revesz; Henry Houlden
Journal:  Neurobiol Aging       Date:  2010-07-21       Impact factor: 4.673

5.  Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.

Authors:  Guangwei Du; Mechelle M Lewis; Michele L Shaffer; Honglei Chen; Qing X Yang; Richard B Mailman; Xuemei Huang
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

6.  Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE.

Authors:  Scott Ayton; Noel G Faux; Ashley I Bush
Journal:  Nat Commun       Date:  2015-05-19       Impact factor: 14.919

Review 7.  Initiation and progression of α-synuclein pathology in Parkinson's disease.

Authors:  George K Tofaris
Journal:  Cell Mol Life Sci       Date:  2022-03-26       Impact factor: 9.207

Review 8.  Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.

Authors:  Scott Ayton; Peng Lei
Journal:  Biomed Res Int       Date:  2014-01-16       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.